BRAIG FRIEDERIKE ET AL: "Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma", ONCOTARGET, vol. 7, no. 28, 12 July 2016 (2016-07-12), pages 42988-42995, XP002780734, (B1)

DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 20 June 2017 (2017-06-20), HO, ALAN LOH (CORRESPONDENCE) ET AL: "An open-label, phase II study of tipifarnib for the treatment of and neck.", XP002780736, retrieved from STN Database accession no. 0052654131 & HO, ALAN LOH (CORRESPONDENCE) ET AL: "An open-label, phase II study of tipifarnib for the treatment of and neck.", JOURNAL OF CLINICAL ONCOLOGY, (20 JUN 2017) VOL. 35, NO. 15, SUPP. SUPPLEMENT 1. MEETING INFO: 2017 ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, ASCO. CHICAGO, IL, UNITED STATES. 02 JUN 2017-06 JUN 2017 ISSN: 0732-183X, 20 June 2017 (2017-06-20), (B1)

anonymous: "Hisory of Changes for Study NCT02383927 Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations", Clinical Trials.gov archive , 12 September 2016 (2016-09-12), page 8pp, XP002780735, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history /NCT02383927?V_7=View#StudyPageTop [retrieved on 2018-05-02] (B1)

WO-A1-2015/164862 (B1)

WO-A1-2017/031101 (B1)

J Vachtenheim ET AL: "Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung", Clinical Cancer Research, vol. 1 1 March 1995 (1995-03-01), pages 359-365, XP055472173, UNITED STATES Retrieved from the Internet: URL:http://clincancerres.aacrjournals.org/ content/clincanres/1/3/359.full.pdf [retrieved on 2018-05-02] (B1)